JPRN-jRCT2080222425未知3 期
Phase 3 Clinical Trial with MD-0901
试验速览
- 阶段
- 3 期
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 16age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1)Subjects who are diagnosed as ulcerative colitis
- •2)Subjects who are total score of 3-8 on the Ulcerative Colitis Disease Activity Index (UC-DAI) with a sigmoidoscopy score of 1 or higher, a rectal bleeding score of 1 or higher and a Physician's Global Assessment (PGA) score of 2 or less at the baseline
- •3)Outpatients
排除标准
- •1)Subjects who are classified to severe ulcerative colitis by severity classification
- •2)Subjects with a history of colectomy (except appendectomy)
- •3)Subjects with moderate/severe renal or liver impairment
- •4)Subjects with serious blood disorder, respiratory disorder, digestive disorder, cardiovascular disorder, psychiatric disorder, metabolic and electrolyte abnormality or hypersensitivity as complication
- •5)Subjects with malignant tumor as complication
研究者
相似试验
未知
3 期
Active Phase Study with MD-0901 -Phase 3 Clinical Trial in Patients with Mild to Moderate Active Ulcerative ColitisMild to moderate active ulcerative colitisJPRN-jRCT2080221343MOCHIDA PHARMACEUTICAL CO., LTD.228
未知
3 期
Remission Phase Study with MD-0901 -Phase 3 Clinical Trial in Patients with Ulcerative Colitis in Remission PhaseJPRN-jRCT2080221344MOCHIDA PHARMACEUTICAL CO., LTD.190
进行中（未招募）
不适用
X01-315-02 / ?A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7R Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma? - Allovectin-7R Immunotherapy for Metastatic Melanoma (A.I.M.M.)Recurrent metastatic melanomaMedDRA version: 9.1Level: LLTClassification code 10027481Term: Metastatic melanomaEUCTR2007-004120-21-ITVICAL INCORPORATED375
招募中
3 期
on-inferiority clinical trial to compare efficacy and safety of Pembrolizumab (CinnaGen Co.) versus Keytruda® in patients with metastatic Non-Small Cell Lung Cancer (NSCLC)IRCT20150303021315N29CinnaGen company295
进行中（未招募）
不适用
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.Patients with confirmed diagnosis of node positive (1-3 nodes)invasive breast carcinoma with positive hormone receptor status, and negative HER-2.MedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000174-37-ESGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)3,500